269 related articles for article (PubMed ID: 22975662)
1. Azilsartan, aliskiren, and combination antihypertensives utilizing renin-angiotensin-aldosterone system antagonists.
Lanier G; Sankholkar K; Aronow WS
Am J Ther; 2014; 21(5):419-35. PubMed ID: 22975662
[TBL] [Abstract][Full Text] [Related]
2. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
[TBL] [Abstract][Full Text] [Related]
3. Single-pill triple-combination therapy: an alternative to multiple-drug treatment of hypertension.
Chrysant SG
Postgrad Med; 2011 Nov; 123(6):21-31. PubMed ID: 22104451
[TBL] [Abstract][Full Text] [Related]
4. Aliskiren/amlodipine combination for the treatment of hypertension.
Billecke SS; Marcovitz PA
Drugs Today (Barc); 2011 Jun; 47(6):403-17. PubMed ID: 21695283
[TBL] [Abstract][Full Text] [Related]
5. The single pill triple combination of aliskiren, amlodipine, and hydrochlorothiazide in the treatment of hypertension.
Huan Y; Townsend R
Expert Opin Pharmacother; 2012 Nov; 13(16):2409-15. PubMed ID: 23067322
[TBL] [Abstract][Full Text] [Related]
6. Aliskiren-based dual- and triple-combination therapies in high-risk US minority patients with stage 2 hypertension.
Ferdinand KC; Weitzman R; Purkayastha D; Sridharan K; Jaimes EA
J Am Soc Hypertens; 2012; 6(3):219-27. PubMed ID: 22305998
[TBL] [Abstract][Full Text] [Related]
7. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.
McMurray JJ; Pitt B; Latini R; Maggioni AP; Solomon SD; Keefe DL; Ford J; Verma A; Lewsey J;
Circ Heart Fail; 2008 May; 1(1):17-24. PubMed ID: 19808266
[TBL] [Abstract][Full Text] [Related]
8. Aliskiren/amlodipine (Tekamlo): another combination tablet for hypertension.
Med Lett Drugs Ther; 2010 Nov; 52(1352):94-5. PubMed ID: 21116232
[No Abstract] [Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of aliskiren/hydrochlorothiazide single-pill combination tablets and free combination of aliskiren and hydrochlorothiazide.
Yan JH; Jarugula V; Sabo R; Papst CC; Zhang J; Dole WP
J Clin Pharmacol; 2012 May; 52(5):645-55. PubMed ID: 21659626
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of aliskiren/amlodipine combination and high-dose amlodipine monotherapy on endothelial function in elderly hypertensive patients.
Fukutomi M; Hoshide S; Mizuno H; Kario K
Am J Hypertens; 2014 Jan; 27(1):14-20. PubMed ID: 24008122
[TBL] [Abstract][Full Text] [Related]
11. Direct renin inhibitor induced renal failure.
Vallakati A; Chandra PA; Hollander G; Shani J
Am J Ther; 2014; 21(2):e53-5. PubMed ID: 23665882
[TBL] [Abstract][Full Text] [Related]
12. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
Dalla Vestra M; Simioni N; Masiero A
Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
[TBL] [Abstract][Full Text] [Related]
13. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
14. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.
Solomon SD; Appelbaum E; Manning WJ; Verma A; Berglund T; Lukashevich V; Cherif Papst C; Smith BA; Dahlöf B;
Circulation; 2009 Feb; 119(4):530-7. PubMed ID: 19153265
[TBL] [Abstract][Full Text] [Related]
15. Hypertension management: rationale for triple therapy based on mechanisms of action.
Neutel JM; Smith DH
Cardiovasc Ther; 2013 Oct; 31(5):251-8. PubMed ID: 23121769
[TBL] [Abstract][Full Text] [Related]
16. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
Horký K
Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
[TBL] [Abstract][Full Text] [Related]
17. Azilsartan medoxomil/chlorthalidone: a new fixed-dose combination antihypertensive.
Pierini D; Anderson KV
Ann Pharmacother; 2013 May; 47(5):694-703. PubMed ID: 23585646
[TBL] [Abstract][Full Text] [Related]
18. Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension.
Deeks ED
Am J Cardiovasc Drugs; 2009; 9(6):411-8. PubMed ID: 19929039
[TBL] [Abstract][Full Text] [Related]
19. First orally active DRI Aliskiren--a new prospect in management of hypertension and beyond.
Sawhney JP
Indian Heart J; 2010; 62(1):49-56. PubMed ID: 21180035
[TBL] [Abstract][Full Text] [Related]
20. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
Bomback AS; Rekhtman Y; Klemmer PJ; Canetta PA; Radhakrishnan J; Appel GB
J Am Soc Hypertens; 2012; 6(5):338-45. PubMed ID: 22995802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
